Literature DB >> 26581538

[Apixaban as therapeutic option in nephropathy patients with heparin-induced thrombocytopenia (HIT)].

Guillermo Delgado-García1, Roberto Monreal-Robles1, Daniel Gallegos-Arguijo1, Javier Marfil-Rivera2.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic condition caused by antibodies against the heparin-PF4 complex. This disorder is even more problematic in patients undergoing hemodialysis since they are repeatedly exposed to heparin. The diagnostic and therapeutic approach is particularly challenging in this population. We report the case of a woman with chronic kidney disease and a high pretest probability for heparin-induced thrombocytopenia who was acutely treated with apixaban, an oral selective factor Xa inhibitor.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26581538

Source DB:  PubMed          Journal:  Gac Med Mex        ISSN: 0016-3813            Impact factor:   0.302


  3 in total

1.  Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement?

Authors:  Matej Samoš; Tomáš Bolek; Ingrid Škorňová; Jakub Benko; Ján Staško; Peter Kubisz; Peter Galajda; Marián Mokán
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

2.  Acute apixaban treatment of heparin-induced thrombocytopenia.

Authors:  Guillermo Delgado-García; Roberto Monreal-Robles
Journal:  J Thromb Thrombolysis       Date:  2017-04       Impact factor: 2.300

3.  Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay.

Authors:  Preethi Ramachandran; Fady Farag; Rewais Morcus; Vladimir Gotlieb
Journal:  Am J Case Rep       Date:  2019-03-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.